Does the media refer more to NUVL or OCUL?

In the previous week, Ocular Therapeutix had 8 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Ocular Therapeutix and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.25 beat Ocular Therapeutix's score of 0.58 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRAX or OCUL?

In the previous week, Ocular Therapeutix had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Ocular Therapeutix and 7 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.67 beat Ocular Therapeutix's score of 0.58 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PCVX or OCUL?

In the previous week, Vaxcyte had 4 more articles in the media than Ocular Therapeutix. MarketBeat recorded 16 mentions for Vaxcyte and 12 mentions for Ocular Therapeutix. Vaxcyte's average media sentiment score of 0.74 beat Ocular Therapeutix's score of 0.58 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, OCUL or LNTH?

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocular Therapeutix $51.95M 42.02 -$265.94M -$1.46 N/A Lantheus $1.54B 4.49 $233.56M $4.15 25.59

Does the media prefer OCUL or LNTH?

In the previous week, Ocular Therapeutix had 9 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Ocular Therapeutix and 3 mentions for Lantheus. Ocular Therapeutix's average media sentiment score of 0.58 beat Lantheus' score of 0.46 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OCUL or SYRE?

In the previous week, Ocular Therapeutix had 4 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Ocular Therapeutix and 8 mentions for Spyre Therapeutics. Ocular Therapeutix's average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.35 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ocular Therapeutix (OCUL) Competitors

$9.97 +0.54 (+5.73%)

Closing price 04:00 PM Eastern

Extended Trading

$9.61 -0.36 (-3.60%)

As of 05:18 PM Eastern

Compare

OCUL vs. NUVL, PRAX, PCVX, LNTH, and SYRE

Should you buy Ocular Therapeutix stock or one of its competitors? MarketBeat compares Ocular Therapeutix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocular Therapeutix include Nuvalent (NUVL), Praxis Precision Medicines (PRAX), Vaxcyte (PCVX), Lantheus (LNTH), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Ocular Therapeutix compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Nuvalent has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Nuvalent's return on equity of -40.11% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Nuvalent has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Nuvalent currently has a consensus target price of $131.15, indicating a potential upside of 6.26%. Ocular Therapeutix has a consensus target price of $24.89, indicating a potential upside of 149.64%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Ocular Therapeutix has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Ocular Therapeutix	$51.95M	42.02	-$265.94M	-$1.46	N/A

In the previous week, Ocular Therapeutix had 8 more articles in the media than Nuvalent. MarketBeat recorded 12 mentions for Ocular Therapeutix and 4 mentions for Nuvalent. Nuvalent's average media sentiment score of 1.25 beat Ocular Therapeutix's score of 0.58 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Ocular Therapeutix beats Nuvalent on 8 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Ocular Therapeutix has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	989.30	-$303.27M	-$13.37	N/A
Ocular Therapeutix	$51.95M	42.02	-$265.94M	-$1.46	N/A

In the previous week, Ocular Therapeutix had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 12 mentions for Ocular Therapeutix and 7 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.67 beat Ocular Therapeutix's score of 0.58 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Praxis Precision Medicines has a beta of 2.71, suggesting that its stock price is 171% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Praxis Precision Medicines' return on equity of -43.02% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Praxis Precision Medicines currently has a consensus target price of $566.21, suggesting a potential upside of 86.63%. Ocular Therapeutix has a consensus target price of $24.89, suggesting a potential upside of 149.64%. Given Ocular Therapeutix's higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Praxis Precision Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Praxis Precision Medicines beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

How does Ocular Therapeutix compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Ocular Therapeutix (NASDAQ:OCUL) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ocular Therapeutix has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Ocular Therapeutix	$51.95M	42.02	-$265.94M	-$1.46	N/A

Vaxcyte presently has a consensus price target of $86.00, suggesting a potential upside of 65.04%. Ocular Therapeutix has a consensus price target of $24.89, suggesting a potential upside of 149.64%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Vaxcyte had 4 more articles in the media than Ocular Therapeutix. MarketBeat recorded 16 mentions for Vaxcyte and 12 mentions for Ocular Therapeutix. Vaxcyte's average media sentiment score of 0.74 beat Ocular Therapeutix's score of 0.58 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Vaxcyte's return on equity of -32.51% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Summary

Vaxcyte beats Ocular Therapeutix on 8 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Lantheus?

Ocular Therapeutix (NASDAQ:OCUL) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	42.02	-$265.94M	-$1.46	N/A
Lantheus	$1.54B	4.49	$233.56M	$4.15	25.59

Ocular Therapeutix presently has a consensus target price of $24.89, suggesting a potential upside of 149.64%. Lantheus has a consensus target price of $101.86, suggesting a potential downside of 4.09%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, research analysts clearly believe Ocular Therapeutix is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Ocular Therapeutix had 9 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Ocular Therapeutix and 3 mentions for Lantheus. Ocular Therapeutix's average media sentiment score of 0.58 beat Lantheus' score of 0.46 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocular Therapeutix has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Ocular Therapeutix's net margin of -558.24%. Lantheus' return on equity of 29.32% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Lantheus	18.05%	29.32%	15.00%

Summary

Ocular Therapeutix and Lantheus tied by winning 8 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Spyre Therapeutics?

Ocular Therapeutix (NASDAQ:OCUL) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Spyre Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Spyre Therapeutics' return on equity of -42.88% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-558.24%	-64.28%	-48.15%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Ocular Therapeutix has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market.

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Spyre Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	42.02	-$265.94M	-$1.46	N/A
Spyre Therapeutics	$890K	9,788.53	-$155.20M	-$2.08	N/A

Ocular Therapeutix currently has a consensus target price of $24.89, suggesting a potential upside of 149.64%. Spyre Therapeutics has a consensus target price of $94.17, suggesting a potential downside of 6.13%. Given Ocular Therapeutix's higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Ocular Therapeutix had 4 more articles in the media than Spyre Therapeutics. MarketBeat recorded 12 mentions for Ocular Therapeutix and 8 mentions for Spyre Therapeutics. Ocular Therapeutix's average media sentiment score of 0.58 beat Spyre Therapeutics' score of 0.35 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spyre Therapeutics beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCUL vs. The Competition

Export

Metric	Ocular Therapeutix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.18B	$2.96B	$6.42B	$12.38B
Dividend Yield	N/A	1.78%	2.68%	5.81%
P/E Ratio	-6.83	18.52	24.82	24.35
Price / Sales	42.02	663.73	571.81	129.00
Price / Cash	N/A	55.91	27.92	37.84
Price / Book	3.25	4.08	10.85	6.58
Net Income	-$265.94M	$64.45M	$3.56B	$336.75M
7 Day Performance	10.90%	1.23%	0.70%	-0.49%
1 Month Performance	21.14%	0.87%	0.28%	1.56%
1 Year Performance	22.63%	28.51%	30.68%	33.77%

Ocular Therapeutix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCUL Ocular Therapeutix	3.3135 of 5 stars	$9.97 +5.7%	$24.89 +149.6%	+16.0%	$2.18B	$51.95M	N/A	230	Analyst Revision
NUVL Nuvalent	1.8541 of 5 stars	$88.49 -2.7%	$141.24 +59.6%	+64.6%	$7.18B	N/A	N/A	40	Positive News
PRAX Praxis Precision Medicines	2.7934 of 5 stars	$253.25 -0.3%	$572.72 +126.1%	+566.8%	$7.08B	$8.55M	N/A	110	News Coverage Gap Up
PCVX Vaxcyte	2.7299 of 5 stars	$46.33 -2.2%	$86.00 +85.6%	+56.5%	$6.84B	N/A	N/A	160
LNTH Lantheus	2.9465 of 5 stars	$100.01 -1.0%	$101.86 +1.8%	+31.2%	$6.57B	$1.54B	24.10	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCUL) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Competitors

OCUL vs. NUVL, PRAX, PCVX, LNTH, and SYRE

How does Ocular Therapeutix compare to Nuvalent?

Summary

How does Ocular Therapeutix compare to Praxis Precision Medicines?

Summary

How does Ocular Therapeutix compare to Vaxcyte?

Summary

How does Ocular Therapeutix compare to Lantheus?

Summary

How does Ocular Therapeutix compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Competitors

OCUL vs. NUVL, PRAX, PCVX, LNTH, and SYRE

How does Ocular Therapeutix compare to Nuvalent?

Is NUVL or OCUL more profitable?

Which has more volatility and risk, NUVL or OCUL?

Do analysts rate NUVL or OCUL?

Which has preferable valuation & earnings, NUVL or OCUL?

Does the media refer more to NUVL or OCUL?

Do insiders and institutionals believe in NUVL or OCUL?

Summary

How does Ocular Therapeutix compare to Praxis Precision Medicines?

Which has better earnings & valuation, PRAX or OCUL?

Does the media refer more to PRAX or OCUL?

Do institutionals and insiders have more ownership in PRAX or OCUL?

Which has more risk and volatility, PRAX or OCUL?

Is PRAX or OCUL more profitable?

Do analysts rate PRAX or OCUL?

Summary

How does Ocular Therapeutix compare to Vaxcyte?

Do insiders and institutionals have more ownership in PCVX or OCUL?

Which has better valuation and earnings, PCVX or OCUL?

Do analysts recommend PCVX or OCUL?

Does the media favor PCVX or OCUL?

Which has more volatility & risk, PCVX or OCUL?

Is PCVX or OCUL more profitable?

Summary

How does Ocular Therapeutix compare to Lantheus?

Which has higher valuation & earnings, OCUL or LNTH?

Do analysts rate OCUL or LNTH?

Do institutionals & insiders hold more shares of OCUL or LNTH?

Does the media prefer OCUL or LNTH?

Which has more volatility and risk, OCUL or LNTH?

Is OCUL or LNTH more profitable?

Summary

How does Ocular Therapeutix compare to Spyre Therapeutics?

Is OCUL or SYRE more profitable?

Which has more risk & volatility, OCUL or SYRE?

Do insiders and institutionals have more ownership in OCUL or SYRE?

Which has preferable valuation & earnings, OCUL or SYRE?

Do analysts prefer OCUL or SYRE?

Does the media prefer OCUL or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools